Gene Therapy

DALLAS – October 29, 2026 -- Nanoscope Therapeutics will field four executives across six sessions at Advanced Therapies USA 2026 in Boston on November 4-5, as its optogenetic gene therapy MOGENRY (sonpiretigene isteparvovec; MCO-010) awaits decisions from the U.S. FDA and Japan's PMDA. The conference, held at the Hynes Convention Center, brings together cell and gene therapy developers, manufacturers, investors and commercial leaders.

AUSTIN – October 29, 2026 -- Genprex (NASDAQ: GNPX) will present research on the TUSC2 gene, the therapeutic payload of its lead lung cancer candidate REQORSA, in mitochondrial biology and cellular aging at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting, widening the scientific case for the asset beyond oncology.

Poster scheduled for Nov. 4 in National Harbor, Maryland

The poster, titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program," will run in Late Breaking Poster Session I from 6:00 to 7:15 p.m. ET at the Gaylord National Resort & Convention Center, Exhibit Hall C-D. Mark S. Berger, MD, Genprex's Chief Medical Officer, will present under Abstract ID 2489375. The meeting runs Nov. 4-7, 2026.

Global – October 27, 2026 -- Solid Biosciences has dosed the first participant in FALCON, a Phase 1b trial of SGT-212, its investigational gene therapy for Friedreich's ataxia (FA), and expects to release an initial data update in the second half of 2026, subject to patient enrollment.

FALCON tests a dual-route gene therapy in adults aged 18-40

FALCON is an open-label, dose-finding study designed to evaluate the safety and tolerability of SGT-212 in people aged 18-40 living with FA. Solid describes the approach as novel and first-in-class. It is the first-in-human study of SGT-212.

Intradentate nucleus infusion precedes intravenous delivery

Each participant receives an intradentate nucleus (IDN) infusion targeting the cerebellar dentate nuclei, followed by an intravenous (IV) infusion. Solid says the dual routes are intended to address the neurologic, cardiac and systemic manifestations of FA.